Main Article Content

Dr. Linu Abraham Jacob, Professor and Head Dr. Animesh Gupta, Senior resident Dr. Kanika Sharma Dr. M C Suresh Babu, Professor Dr. Lokesh K. N., Associate Professor Dr. A H Rudresha, Associate Professor Dr. Rajeev L. K.,, Associate Professor Dr. Smitha C. Saldanha, Associate Profesor Dr. Usha Amirtham, Professor and Head


PURPOSE - Diffuse Large B-Cell Lymphoma can be subclassified into the prognostically distinct groups of GCB and non-GCB using the immunohistochemical Hans algorithm. However, in real life, patients classified as GCB show differing outcomes even when treated with the same chemotherapy regimen. CD10 is a GCB marker, while MUM1 is a non-GCB marker, but Hans algorithm classifies CD10+ MUM1+ patients as GCB DLBCL. We explored whether CD10+ MUM1+ GCB DLBCL patients had different outcomes compared to rest of the GCB DLBCL patients.

METHODS - In this study, we retrospectively analyzed the clinical records of 427 DLBCL patients treated with standard chemo-immunotherapy at Kidwai Memorial Institute of Oncology, Bengaluru from 2013 to 2019. The clinical characteristics, response rate and overall survival of CD10+ MUM1+ GCB group was compared with MUM1-ve GCB group and non-GCB group.

RESULTS - Among the patients studied, 187 (43%) patients were of GCB subtype, whereas 240 (57%) patients belonged to the non-GCB subtype. Additionally, 61 (14.3%) patients were of the CD10+ MUM1+ GCB immune-phenotype. No significant differences could be demonstrated in the clinical characteristics of CD10+ MUM1+ GCB and MUM1- GCB patients. Patients with CD10+ MUM1+ GCB subtype exhibited a significantly inferior response rate compared to those with MUM1- GCB subtype (81% versus 92%; p=0.04). Although, both non-GCB and CD10+ MUM1+ GCB subtypes displayed diminished overall survival in comparison to MUM1- GCB patients, (non-GCB = 33 months, CD10+ MUM1+ GCB = 33 months and MUM1-ve GCB = 40.4 months, p = 0.21) it did not reach statistical significance

CONCLUSION - CD10+ MUM1+ GCB patients may be prognostically more similar to non-GCB patients, as suggested by the inferior response rates and numerically inferior OS compared to other GCB patients. This needs further confirmation in prospective studies.

Keywords: Immunohistochemistry, Gene expression, Cell of origin, chemo-immunotherapy, Germinal centre B- cell

Article Details

How to Cite
JACOB, Dr. Linu Abraham et al. THE PROGNOSTIC SIGNIFICANCE OF CD10+ MUM1+ GCB SUBTYPE OF DIFFUSE LARGE B-CELL LYMPHOMAS. Medical Research Archives, [S.l.], v. 12, n. 6, june 2024. ISSN 2375-1924. Available at: <>. Date accessed: 22 july 2024. doi:
Research Articles


1. Perry AM, Diebold J, Nathwani BN, et al. Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project. Haematologica. 2016;101(10):1244-1250. doi:

2. Anderson. Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centre-like tumours displaying different survival characteristics. International Journal of Oncology. 2009;35(05). doi:

3. Ruppert AS, Dixon JG, Salles GA, et al. International prognostic indices in diffuse large B-cell lymphoma (DLBCL): a comparison of IPI, R-IPI and NCCN-IPI. Blood. Published online March 13, 2020.

4. Nowakowski GS, Czuczman MS. ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection? American Society of Clinical Oncology Educational Book. 2015; (35):e449-e457. doi:

5. Hans CP. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282. doi:

6. William W.L. Choi, Weisenburger DD, Greiner TC, et al. A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy. Clinical Cancer Research. 2009;15 (17):5494-5502. doi:

7. Muris J, Meijer C, Vos W, et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. The Journal of Pathology. 2006;208(5):714-723. doi:

8. Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837-842.

9. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. Journal of Clinical Oncology. 2014;32(27):3059-3067. doi:

10. K Benesova, K Forsterova, H Votavova, et al. The Hans algorithm failed to predict outcome in patients with diffuse large B-cell lymphoma treated with rituximab. Neoplasma. 2012;60 (01):68-73. doi:

11. Gutiérrez-García G, Cardesa-Salzmann T, Climent F, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood. 2011;117(18):4836-4843. doi:

12. Eisuke Shiozawa, Yamochi-Onizuka T, Takimoto M, Ota H. The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries. Leukemia research. 2007; 31(11):1579-1583. doi:

13. Ajay Gogia, Nair S, Arora S, et al. Impact of Cell-of-Origin on Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Uniform R-CHOP Protocol: A Single-Center Retrospective Analysis From North India. Frontiers in oncology. 2021;11. doi:

14. Read JA, Koff JL, Nastoupil LJ, Williams JN, Cohen JB, Flowers CR. Evaluating Cell-of-Origin Subtype Methods for Predicting Diffuse Large B-Cell Lymphoma Survival: A Meta-Analysis of Gene Expression Profiling and Immunohistochemistry Algorithms. Clinical Lymphoma Myeloma and Leukemia. 2014;14 (6):460-467.e2. doi:

15. Thunberg U, Enblad G, Berglund M. Classification of diffuse large B-cell lymphoma by immunohistochemistry demonstrates that elderly patients are more common in the non-GC subgroup and younger patients in the GC subgroup. Haematologica. 2012;97(2):e3. doi:

16. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells. Journal of Experimental Medicine. 2001;194(12): 1861-1874. doi:

17. Kim M, Suh C, Kim J, Jung Yong Hong. Difference of Clinical Parameters between GCB and Non-GCB Subtype DLBCL. Blood. 2017;130:5231-5231. doi:

18. Castellino A, Chiappella A, LaPlant BR, et al. Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials. Blood Cancer Journal. 2018;8(11):108. doi:

19. Younes A, Sehn LH, Johnson P, et al. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2019;37(15):1285-1295. doi:

20. Lu TX, Miao Y, Wu JZ, et al. The distinct clinical features and prognosis of the CD10+ MUM1+ and CD10−Bcl6−MUM1− diffuse large B-cell lymphoma. Scientific Reports. 2016;6. doi:

21. Chung Che Chang, McClintock S, Cleveland RP, et al. Immunohistochemical Expression Patterns of Germinal Center and Activation B-cell Markers Correlate With Prognosis in Diffuse Large B-cell Lymphoma. The American Journal of Surgical Pathology. 2004;28(4):464-470. doi:

22. ColomoL, López-GuillermoA, PeralesM, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood. 2003;101(1):78-84.

23. Bai M, Angelos Skyrlas, Agnantis NJ, et al. B-cell differentiation, apoptosis and proliferation in diffuse large B-cell lymphomas. PubMed. 2005;25(1A):347-362.